journal
Journals Cancer Research and Treatment ...

Cancer Research and Treatment : Official Journal of Korean Cancer Association

https://read.qxmd.com/read/38754473/a-10-gene-signature-to-predict-the-prognosis-of-early-stage-triple-negative-breast-cancer
#1
JOURNAL ARTICLE
Chang Min Kim, Kyong Hwa Park, Yun Suk Yu, Ju Won Kim, Jin Young Park, Kyunghee Park, Jong-Han Yu, Jeong Eon Lee, Sung Hoon Sim, Bo Kyoung Seo, Jin Kyeoung Kim, Eun Sook Lee, Yeon Hee Park, Sun-Young Kong
PURPOSE: Triple-negative breast cancer (TNBC) is a particularly challenging subtype of breast cancer, with a poorer prognosis compared to other subtypes. Unfortunately, unlike luminal type cancers, there is no validated biomarker to predict the prognosis of patients with early-stage TNBC. Accurate biomarkers are needed to establish effective therapeutic strategies. MATERIALS AND METHODS: In this study, we analyzed gene expression profiles of tumor samples from 184 TNBC patients (training cohort, n=76; validation cohort, n=108) using RNA sequencing...
May 10, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38726507/long-term-psychiatric-and-endocrine-complications-following-hematopoietic-stem-cell-transplantation-in-hematologic-disease-in-korea-a-nation-wide-cohort-study
#2
JOURNAL ARTICLE
Min Ji Jeon, Eunjin Noh, Seok Joo Moon, Eun Sang Yu, Chul Won Choi, Dae Sik Kim, Eun Joo Kang
PURPOSE: Numerous patients experience long-term complications after HSCT. This study aimed to identify the frequency and risk factors for psychiatric and endocrine complications following HSCT through big data analyses. MATERIALS AND METHODS: We established a cohort of patients with hematologic disease who underwent HSCT in Korea between 2010 and 2012 using the Health Insurance Review & Assessment Service data. A total of 3,636 patients were identified, and insurance claims were tracked using psychiatric and endocrine diagnostic International Classification of Diseases-10th Revision codes for the ensuing decade...
May 9, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38726510/precision-oncology-clinical-trials-a-systematic-review-of-phase-ii-clinical-trials-with-biomarker-driven-adaptive-design
#3
JOURNAL ARTICLE
Hyerim Ha, Hee Yeon Lee, Jee Hyun Kim, Do Yeun Kim, Ho Jung An, SeungJin Bae, Hye-Sung Park, Jin Hyoung Kang
PURPOSE: Novel clinical trial designs are conducted in the precision medicine era. This study aimed to evaluate biomarker-driven, adaptive phase II trials in precision oncology, focusing on infrastructure, efficacy, and safety. MATERIALS AND METHODS: We systematically reviewed and analyzed the target studies. EMBASE and PubMed searches from 2015 to 2023 generated 29 eligible trials. Data extraction included infrastructure, biomarker screening methodologies, efficacy, and safety profiles...
May 7, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38726509/clinical-and-radiologic-predictors-of-response-to-atezolizumab-bevacizumab-in-advanced-hepatocellular-carcinoma
#4
JOURNAL ARTICLE
Se Jin Choi, Sung Won Chung, Jonggi Choi, Kang Mo Kim, Hyung-Don Kim, Changhoon Yoo, Baek-Yeol Ryoo, Seung Soo Lee, Won-Mook Choi, Sang Hyun Choi
PURPOSE: This study aimed to identify clinical and radiologic characteristics that could predict response to atezolizumab-bevacizumab combination therapy in patients with advanced hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This single-center retrospective study included 108 advanced HCC patients with intrahepatic lesions who were treated with atezolizumab-bevacizumab. Two radiologists independently analyzed Imaging characteristics of the index tumor on pretreatment computed tomography...
May 7, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38726508/evaluation-of-molecular-residual-disease-by-a-fixed-panel-in-resectable-colorectal-cancer
#5
JOURNAL ARTICLE
Jian Yang, Chengqing Yu, Haoran Li, Di Peng, Qiaoxia Zhou, Jun Yao, Juan Lv, Shuai Fang, Jiaochun Shi, Yijun Wei, Guoqiang Wang, Shangli Cai, Zhihong Zhang, Zixiang Zhang, Jian Zhou
PURPOSE: Molecular residual disease (MRD) is a promising biomarker in colorectal cancer (CRC) for prognosis and guiding treatment, while the whole-exome sequencing (WES) based tumor-informed assay is standard for evaluating MRD based on circulating tumor DNA (ctDNA). In this study, we assessed the feasibility of a fixed-panel for evaluating MRD in CRC. MATERIALS AND METHODS: 75 patients with resectable stage I-III CRC were enrolled. Tumor tissues obtained by surgery, and pre-operative and post-operative day 7 blood samples were collected...
May 7, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38697848/adjuvant-pembrolizumab-in-patients-with-stage-iiia-n2-non-small-cell-lung-cancer-completely-resected-after-neoadjuvant-concurrent-chemoradiation-a-prospective-open-label-single-arm-phase-2-trial
#6
JOURNAL ARTICLE
Junghoon Shin, Sehhoon Park, Kyung Hwan Kim, Eui-Cheol Shin, Hyun Ae Jung, Jong Ho Cho, Jong-Mu Sun, Se-Hoon Lee, Yong Soo Choi, Jin Seok Ahn, Jhingook Kim, Keunchil Park, Young Mog Shim, Hong Kwan Kim, Jae Myoung Noh, Yong Chan Ahn, Hongryull Pyo, Myung-Ju Ahn
PURPOSE: Optimal treatment for stage IIIA/N2 non-small cell lung cancer (NSCLC) is controversial. We aimed to assess the efficacy and safety of adjuvant pembrolizumab for stage IIIA/N2 NSCLC completely resected after neoadjuvant concurrent chemoradiation therapy (CCRT). MATERIALS AND METHODS: In this open-label, single-center, single-arm phase 2 trial, patients with stage IIIA/N2 NSCLC received adjuvant pembrolizumab for up to two years after complete resection following neoadjuvant CCRT...
April 30, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38697847/efficacy-of-lenvatinib-combined-with-anti-pd-1-antibodies-plus-transcatheter-arterial-chemoembolization-for-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus-a-retrospective-multicenter-study
#7
JOURNAL ARTICLE
Xiangye Ou, Junyi Wu, Jiayi Wu, Yangkai Fu, Zhenxin Zeng, Shuqun Li, Yinan Li, Deyi Liu, Han Li, Bin Li, Jianyin Zhou, Shaowu Zhuang, Shuqun Cheng, Zhibo Zhang, Kai Wang, Shuang Qu, Maolin Yan
PURPOSE: The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) is extremely poor, and systemic therapy is currently the mainstream treatment. This study aimed to assess the efficacy and safety of lenvatinib combined with anti-PD-1 antibodies and transcatheter arterial chemoembolization (triple therapy) in patients with HCC and PVTT. MATERIALS AND METHODS: This retrospective multicenter study included patients with HCC and PVTT who received triple therapy, were aged between 18 and 75 years, classified as Child Pugh class A or B, and had at least one measurable lesion...
April 30, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38697846/data-resource-profile-the-cancer-public-library-database-in-south-korea
#8
JOURNAL ARTICLE
Dong-Woo Choi, Minyeong Guk, Hyeri Kim, Kwang Sun Ryu, Hyun-Joo Kong, Hyo Soung Cha, Hyun-Jin Kim, Heejung Chae, Young Sang Jeon, Hwanhee Kim, JipMin Jung, Jeong-Soo Im, Kui Son Choi
This paper provides a comprehensive overview of the Cancer Public Library Database (CPLD), established under the Korean Clinical Data Utilization for Research Excellence project (K-CURE). The CPLD links data from four major population-based public sources: the Korea National Cancer Incidence Database in the Korea Central Cancer Registry, cause-of-death data in Statistics Korea, the National Health Information Database in the National Health Insurance Service, and the National Health Insurance Research Database in the Health Insurance Review & Assessment Service...
April 30, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38697850/longitudinal-comparative-analysis-of-circulating-tumor-dna-and-matched-tumor-tissue-dna-in-patients-with-metastatic-colorectal-cancer-receiving-palliative-first-line-systemic-anti-cancer-therapy
#9
JOURNAL ARTICLE
Seung-Been Lee, Ji-Won Kim, Hong-Geun Kim, Sung-Hyun Hwang, Kui-Jin Kim, Ju Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Nak-Jung Kwon, Keun-Wook Lee
PURPOSE: This study aimed to compare tumor tissue DNA (ttDNA) and circulating tumor DNA (ctDNA) to explore the clinical applicability of ctDNA and to better understand clonal evolution in patients with metastatic colorectal cancer undergoing palliative first-line systemic therapy. MATERIALS AND METHODS: We performed targeted sequencing analysis of 88 cancer-associated genes using germline DNA, ctDNA at baseline (baseline-ctDNA), and ctDNA at progressive disease (PD-ctDNA)...
April 29, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38697849/varlitinib-and-paclitaxel-for-egfr-her2-co-expressing-advanced-gastric-cancer-a-multicenter-phase-ib-ii-study-k-master-13
#10
JOURNAL ARTICLE
Dong-Hoe Koo, Minkyu Jung, Yeul Hong Kim, Hei-Cheul Jeung, Dae Young Zang, Woo Kyun Bae, Hyunki Kim, Hyo Song Kim, Choong-Kun Lee, Woo Sun Kwon, Hyun Cheol Chung, Sun Young Rha
PURPOSE: Varlitinib is a pan-human epidermal growth (HER) inhibitor targeting epidermal growth factor receptor (EGFR), HER2, and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC). MATERIALS AND METHODS: Patients whose tumors with EGFR and HER2 overexpression by immunohistochemistry (IHC) (≥1+) were enrolled. Varlitinib and paclitaxel were investigated every 4 weeks...
April 29, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38665055/the-impact-of-infectious-mononucleosis-history-on-the-risk-of-developing-lymphoma-and-nasopharyngeal-carcinoma-a-retrospective-large-scale-cohort-study-using-national-health-insurance-data-in-south-korea
#11
JOURNAL ARTICLE
So Hee Kang, Yun-Hee Lee, Jun-Pyo Myong, Minsu Kwon
PURPOSE: This study aimed to assess the long-term risks associated with a history of infectious mononucleosis (IM), primarily caused by the Epstein-Barr virus (EBV). Specifically analyzing the potential increase in developing nasopharyngeal cancer (NPC) and lymphoma in patients with a history of IM and exploring the prevalence of other EBV-associated conditions. MATERIALS AND METHODS: The Korean National Health Insurance Service (NHIS) database was utilized for a retrospective analysis, covering data from 2002 to 2021...
April 23, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38637965/association-between-endoscopist-volume-and-interval-cancers-after-colonoscopy-results-from-the-national-colorectal-cancer-screening-program-in-korea
#12
JOURNAL ARTICLE
Dong Jun Kim, Nan-He Yoon, Jae Kwan Jun, Mina Suh, Sunhwa Lee, Seongju Kim, Ji Eun Kim, Hooyeon Lee
PURPOSE: The rate of interval colorectal cancer (iCRC) is now accepted as a key performance indicator of organized colorectal cancer (CRC) screening programs. We aimed to examine the association between endoscopist volumes and the rate of iCRC among individuals with a positive fecal immunochemical test (FIT) within a nationwide population-based CRC screening program. MATERIALS AND METHODS: Individuals aged ≥50 years who underwent colonoscopy after a positive FIT from January 1, 2019 until December 31, 2020 in the Korean National Cancer Screening Program (KNCSP) were enrolled...
April 16, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38637966/analysis-of-response-and-progression-patterns-of-tyrosine-kinase-inhibitors-in-recurrent-or-metastatic-adenoid-cystic-carcinoma-a-post-hoc-analysis-of-two-kcsg-phase-ii-trials
#13
JOURNAL ARTICLE
Youjin Kim, Bhumsuk Keam, Eun Joo Kang, Jin-Soo Kim, Hye Ryun Kim, Keun-Wook Lee, Jung Hye Kwon, Kyoung Eun Lee, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Moon Young Choi, Ki Hyeong Lee, Sung-Bae Kim, Myung-Ju Ahn
PURPOSE: In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). MATERIALS AND METHODS: We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed...
April 15, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38637967/effector-function-characteristics-of-exhausted-cd8-t-cell-in-microsatellite-stable-and-unstable-gastric-cancer
#14
JOURNAL ARTICLE
Dong-Seok Han, Yoonjin Kwak, Seungho Lee, Soo Kyung Nam, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Nak-Jung Kwon, Hye Seung Lee, Han-Kwang Yang
PURPOSE: Gastric cancer exhibits molecular heterogeneity, with the microsatellite instability high (MSI-H) subtype drawing attention for its distinct features. Despite a higher survival rate, MSI-H gastric cancer lack significant benefits from conventional chemotherapy. The immune checkpoint inhibitors (ICIs), presents a potential avenue, but a deeper understanding of the tumor immune microenvironment of MSI-H gastric cancer is essential. MATERIALS AND METHODS: We explored the molecular characteristics of CD8+ T cell subtypes in three MSI-H and three microsatellite stable (MSS) gastric cancer samples using single-cell RNA sequencing and spatial transcriptome analysis...
April 12, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38605662/prognostic-significance-of-bulky-nodal-disease-in-anal-cancer-management-a-multi-institutional-study
#15
JOURNAL ARTICLE
Seok-Joo Chun, Eunji Kim, Won Il Jang, Mi-Sook Kim, Hyun-Cheol Kang, Byoung Hyuck Kim, Eui Kyu Chie
PURPOSE: This study aimed to assess the prognostic significance of bulky nodal involvement in patients with anal squamous cell carcinoma treated with definitive chemoradiotherapy. MATERIALS AND METHODS: We retrospectively analyzed medical records of patients diagnosed with anal squamous cell carcinoma who underwent definitive chemoradiotherapy at three medical centers between 2004 and 2021. Exclusion criteria included distant metastasis at diagnosis, 2D radiotherapy, and salvage treatment for local relapse...
April 11, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38605661/identification-of-new-pathogenic-variants-of-hereditary-diffuse-gastric-cancer
#16
JOURNAL ARTICLE
Seung-Young Oh, Giyong Jang, Jaeryuk Kim, Kyoung-Yun Jeong, Hyun Myong Kim, Yoon Jin Kwak, Seong-Ho Kong, Do Joong Park, Hyuk-Joon Lee, Sung-Yup Cho, Jong-Il Kim, Han-Kwang Yang
PURPOSE: Hereditary diffuse gastric cancer (HDGC) presents a significant genetic predisposition, notably linked to mutations in the CDH1 and CTNNA1. However, the genetic basis for over half of HDGC cases remains unidentified. The aim of this study is to identify novel pathogenic variants in HDGC and evaluate their protein expression. MATERIALS AND METHODS: Among 20 qualifying families, two were selected based on available pedigree and DNA. Whole genome sequencing (WGS) on DNA extracted from blood and whole exome sequencing (WES) on DNA from formalin-fixed paraffin-embedded tissues were performed to find potential pathogenic variants in HDGC...
April 11, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38605663/development-and-feasibility-evaluation-of-smart-cancer-care-2-0-based-on-patient-reported-outcomes-for-post-discharge-management-of-patients-with-cancer
#17
JOURNAL ARTICLE
Jin Ah Kwon, Songsoo Yang, Su-Jin Koh, Young Ju Noh, Dong Yoon Kang, Sol Bin Yang, Eun Ji Kwon, Jeong-Wook Seo, Jin Sung Kim, Minsu Ock
PURPOSE: A "Smart Cancer Care" platform that integrates patient-reported outcomes (PROs) with management has been established in Korea. This study focused on improving health behaviors and connecting patients to welfare services by introducing and assessing the feasibility of "Smart Cancer Care 2.0," an enhanced version designed for monitoring complications post-cancer treatment. MATERIALS AND METHODS: Smart Cancer Care 2.0 was developed by conducting a literature review and consulting with expert panels to identify symptoms or variables requiring monitoring and management guidelines based on the treatment type...
April 9, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38514195/dural-metastasis-in-breast-cancer-mri-based-morphological-subtypes-and-their-clinical-implications
#18
JOURNAL ARTICLE
Sung Jun Ahn, Bio Joo, Mina Park, Hun Ho Park, Sang Hyun Suh, Sung Gwe Ahn, Jihwan Yoo
PURPOSE: To investigate the clinical factors associated with breast cancer (BRCA) dural metastases (DMs), their impact on prognosis compared to brain parenchymal metastases (BPMs) alone, and differences between DM subtypes, aiming to inform clinical decisions. MATERIALS AND METHODS: We retrospectively analyzed 119 patients with BRCA with brain metastasis, including 91 patients with BPM alone and 28 patients with DM. Univariate and multivariate analyses were performed to compare the clinical characteristics between the two groups and within subtypes of DM...
March 19, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38487832/cancer-statistics-in-korea-incidence-mortality-survival-and-prevalence-in-2021
#19
JOURNAL ARTICLE
Eun Hye Park, Kyu-Won Jung, Nam Ju Park, Mee Joo Kang, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo
PURPOSE: The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2021. MATERIALS AND METHODS: Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2021, with survival follow-up until December 31, 2022. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea...
March 13, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/38487833/prediction-of-cancer-incidence-and-mortality-in-korea-2024
#20
JOURNAL ARTICLE
Kyu-Won Jung, Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo
PURPOSE: This study aimed to report the projected cancer incidence and mortality for the year 2024 to estimate Korea's current cancer burden. MATERIALS AND METHODS: Cancer incidence data from 1999 to 2021 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2022 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against their respective years and multiplying the projected age-specific rates by the anticipated age-specific population for 2024...
March 11, 2024: Cancer Research and Treatment: Official Journal of Korean Cancer Association
journal
journal
40285
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.